GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (NYSE:BSX) » Definitions » Intrinsic Value: Projected FCF

Boston Scientific (Boston Scientific) Intrinsic Value: Projected FCF

: $19.20 (As of Today)
View and export this data going back to 1992. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-17), Boston Scientific's Intrinsic Value: Projected FCF is $19.20. The stock price of Boston Scientific is $67.96. Therefore, Boston Scientific's Price-to-Intrinsic-Value-Projected-FCF of today is 3.5.

The historical rank and industry rank for Boston Scientific's Intrinsic Value: Projected FCF or its related term are showing as below:

BSX' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.58   Med: 2.73   Max: 3.87
Current: 3.54

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Boston Scientific was 3.87. The lowest was 1.58. And the median was 2.73.

BSX's Price-to-Projected-FCF is ranked worse than
80.99% of 342 companies
in the Medical Devices & Instruments industry
Industry Median: 1.655 vs BSX: 3.54

Boston Scientific Intrinsic Value: Projected FCF Historical Data

The historical data trend for Boston Scientific's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.63 13.32 14.91 16.78 19.20

Boston Scientific Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.78 16.56 17.69 18.28 19.20

Competitive Comparison

For the Medical Devices subindustry, Boston Scientific's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific Price-to-Projected-FCF Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Price-to-Projected-FCF falls into.



Boston Scientific Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Boston Scientific's Free Cash Flow(6 year avg) = $1,068.64.

Boston Scientific's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(12.100819886097*1068.64+19281*0.8)/1476.700
=19.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boston Scientific  (NYSE:BSX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Boston Scientific's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=67.96/19.202424434942
=3.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boston Scientific Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific (Boston Scientific) Business Description

Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Executives
Joseph Michael Fitzgerald officer: SVP & President, Endovascular C/O BOSTON SCIENTIFIC, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Jeffrey B. Mirviss officer: SVP&Pres, Periph Intervent C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Wendy Carruthers officer: SVP, Human Resources C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Arthur C Butcher officer: SVP&Pres, Endoscopy C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Michael F Mahoney officer: President BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Vance R Brown officer: SVP, GC and Corp. Secretary C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Susan E Morano director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jessica L Mega director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Thepaut Eric Francis Yves officer: SVP & Pres, Europe C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
John Bradley Sorenson officer: SVP, Glob Ops & Qual C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jonathan Monson officer: VP, Corp Controller and CAO C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Daniel J. Brennan officer: EVP and CFO BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Nelda J Connors director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Scott Olson officer: SVP & Pres, Rhythm Management C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752

Boston Scientific (Boston Scientific) Headlines